Photo: andresr/Getty Images
Weight-loss company Noom has acquired 503A pharmacy Tailor Made Compounding, which Noom said will allow it to expand its behavior change programs and move beyond weight health.
Tailor Made provides sterile and non-sterile compounding through its pharmacy practice focused on aging. It offers compounded drugs, including hormone replacement therapies and peptide therapies, as well as pharmacist-formulated supplements and cosmetics.
The company works in men's and women's health, weight management, anti-aging and IV therapy, and touts a customer base of more than 400 clinics and numerous telehealth partners.
It also has a compounding facility that is more than 40,000 square feet, located in Kentucky.
Noom said the acquisition will allow it to expand into conditions beyond weight health and deliver "prescription-grade wellness at scale." It said the purchase will add to its healthy aging programs and increase the therapies available to Noom members.
Tailor Made will continue operating as a wholly owned subsidiary under its current leadership.
"Weight health is the entry point to preventive care – and foundational to healthy aging," Geoff Cook, CEO of Noom, said in a statement.
"But it's not the endpoint," he added. "This acquisition continues Noom's expansion into healthy aging, supporting Noom's mission to empower everyone, everywhere to live better, longer – every day. With the acquisition, we plan to broaden our formulary to include peptide-based therapies, like sermorelin, and healthy aging interventions, like NAD+, as we further expand the conditions we serve beyond weight and hormonal health."
THE LARGER TREND
Noom has announced several partnerships over the past year.
In December, Noom and Castlight Health announced exclusively through MobiHealthNews that Noom's weight-loss, diabetes and GLP-1-related programs, including Noom Weight, Noom Diabetes and Noom Med, would be integrated into Castlight's app and healthcare navigation services.
That same month, the company announced an expanded partnership with at-home testing and care delivery company Ash to combine Noom's personalized microdoses of GLP-1 medication and its digital healthy habits platform with Ash's at-home biomarker testing.
In October, Noom announced a partnership with Highmark to provide its weight management offerings to Highmark health plan members.
In April 2025, Noom announced an agreement with Eli Lilly's LillyDirect pharmacy provider, Gifthealth, to improve access to FDA-approved Zepbound (tirzepatide) single-dose vials for Noom's members with an on-label prescription from a doctor.
